Clinical Trials

257 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT07533123 2026-04-16

A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care

364 enrolled

Triple Negative Breast Neoplasms

NCT07007559 2026-04-13

ASPEN-09-03

120 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06632327 2026-04-07

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT07001618 2026-04-03

IMMUNOLIFE2

162 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05999994 2026-03-27

CAMPFIRE

105 enrolled

Tumor-Agnostic

Neoplasms

NCT07203729 2026-03-16

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

184 enrolled

Breast Neoplasms

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

90 enrolled

Breast Neoplasms

NCT06435429 2026-02-10

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

550 enrolled

Metastatic HER2-positive Breast Cancer

NCT05300282 2026-01-28

FIL_A-BEGEV

Phase 1/2 Recruiting

122 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT06576635 2026-01-20

LUNG-05

Phase NA Recruiting

29 enrolled

NSCLC

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

472 enrolled

Tumor-Agnostic

Neoplasms

NCT06908304 2026-01-12

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

300 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

NCT06690840 2026-01-05

AZALEA

45 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06908993 2025-12-17

COMET

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07088263 2025-12-11

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

192 enrolled

Breast Neoplasms

NCT06081959 2025-12-05

Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT06079983 2025-09-12

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

400 enrolled

Breast Neoplasms

NCT06023641 2025-08-19

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

135 enrolled

Sarcoma

Rhabdomyosarcoma

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT06500494 2025-07-24

VINOREAL

Recruiting

368 enrolled

Advanced Breast Cancer

NCT06383767 2025-06-19

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

378 enrolled

Breast Neoplasms

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma